

77. Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E. Effect of oral estradiol and other lipoproteins in postmenopausal women. A randomised, double blind placebo-controlled, cross-over study. Arch Intern Med 1996; 156: 866-872.
78. Whitcroft SI, Crook D, Marsh MS. Long term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 1994; 84: 1-5.
79. Jensen J, Christiansen C. Dose-response effects on serum lipids and lipoproteins following combined oestrogen-progestogen therapy in postmenopausal women. Maturitas 1987; 9: 259-266.
80. Murai A, Miyahara T, Fujimoto N, Matzuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204.
81. Heinrich J, Sandkamp M, Kokott R, Schulte M, Assman G. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950-1954.
82. Schwartzman R, Cox I, Poloniecki J, Crook R, Seymour C, Kaski J. Elevated plasma lipoprotein (a) associated with coronary artery disease patients with chronic stable angina pectoris. J Am Coll Cardiol 1998; 31: 1260-1266.
83. Solymoss B, Marcil M, Wesolowska E, Gilfix B, Lesperance J, Campeau A. Relation of coronary artery disease in women aged less than 60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high density cholesterol ratio. Am J Cardiol 1993; 72: 1215-1219.
84. Ridker P, Hennekens C, Stampfer A. A prospective study of lipoprotein (a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199.
85. Cantin B, Cargnon F, Moorjani S. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-525.
86. Boston A, Cagnon D, Cupples L. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease women: the Framingham Heart Study. Circulation 1994; 90: 1688-1695.
87. Seed M, Hopplcher F, Reaveley D. Relation of lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary artery disease in familial hypercholesterolaemia. N Engl J Med 1990; 322: 1494-1499.
88. Cremer P, Nagel D, Labrot B. Lipoprotein (a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-453.
89. Wolfe BM, Huff MW. Effect of low dosage progestin-only administration upon plasma triglycerides and lipoprotein metabolism in postmenopausal women. J Clin Invest 1993; 92: 456-461.
90. Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995; 49: 87-90.
91. Miller VT, Bush T, Wood PD. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 1995; 273: 199-205.

Fe de errores

En la tabla 1 del editorial del volumen 28 número 6, junio-julio de 2001 se deslizaron dos errores involuntarios:

Donde dice *C. por síndrome fetal debe decir sufrimiento fetal.*

La mortalidad perinatal indicada en %, evidentemente debe ser el mismo valor en ‰.